Article Text


56 Safety of High-Dose Erythopoietin for Neuroprotection in Preterm Infants
  1. JC Fauchere1,
  2. BM Koller1,
  3. A Tschopp2,
  4. HU Bucher1 Swiss EPO Neuroprotection Trial Group
  1. 1Division of Neonatology, Univ. Hospital Zurich
  2. 2Biostatistics, Institute of Social and Preventive Medicine, Univ. Zurich, Zurich, Switzerland


Background Erythropoietin has been shown to be protective against hypoxic-ischaemic and inflammatory injuries in cell culture, animal models of brain injury, and in clinical trials in human adults. A multicentre randomized placebo-controlled trial was started to investigate whether early administration of high dose recombinant human erythropoietin (rhEpo) in very preterm infants improves neuro-developmental outcome at 24 months.

Aim Interim analysis of neonatal complications until discharge from hospital.

Results 395 preterm infants were recruited in 5 centres. 206 infants had received (n t ) 3,000 U/kg body weight rhEpo, and 189 infants NaCl 0.9% intravenously at 3, 12–18 and 36–42 hours after birth.

Abstract 56 Table 1

Conclusions No significant adverse effects of early high-dose rhEpo treatment in very preterm infants were identified. The neuroprotective effect will be evaluated in 24 months.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.